MEI Pharma, Inc.
3611 Valley Centre Drive, Suite #500
About MEI Pharma, Inc.
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in Phase II clinical studies for advanced hematologic diseases. The Company is also developing ME-344, a novel mitochondrial inhibitor that has shown evidence of clinical activity in refractory solid tumors, and ME-401 (formerly PWT143), a highly selective, oral PI3K delta inhibitor. For more information, please visit www.meipharma.com.
CEO: Daniel Gold, PhD
Please click here for clinical trial information.
Please click here for Mei Pharma job opportunities.
296 articles with MEI Pharma, Inc.
Orphan Drug Status Granted for Marshall Edwards, Inc.' Investigational Anti-Cancer Drug Triphendiol (NV-196)
Marshall Edwards, Inc. Release: European Symposium Focuses on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
New Website Launched to Inform Patients with Recurrent Ovarian Cancer about the OVATURE Clinical Research Study
Marshall Edwards, Inc. Release: A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Marshall Edwards, Inc. Release: First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Marshall Edwards, Inc. Newly Published Research Indicates the Potential of Phenoxodiol to Protect Against Neuropathy
Marshall Edwards, Inc. New Research Results Show That Investigational Drug Phenoxodiol Targets Cancer Protein, Causing Cancer Cell Death
Marshall Edwards, Inc. Announces Initial Trial Sites, Principle Investigator For Phase III OVATURE Trial For Phenoxodiol